MeCP2 regulates gene expression through recognition of H3K27me3

MeCP2 plays a multifaceted role in gene expression regulation and chromatin organization. Interaction between MeCP2 and methylated DNA in the regulation of gene expression is well established. However, the widespread distribution of MeCP2 suggests it has additional interactions with chromatin. Here we demonstrate, by both biochemical and genomic analyses, that MeCP2 directly interacts with nucleosomes and its genomic distribution correlates with that of H3K27me3. In particular, the methyl-CpG-binding domain of MeCP2 shows preferential interactions with H3K27me3. We further observe that the impact of MeCP2 on transcriptional changes correlates with histone post-translational modification patterns. Our findings indicate that MeCP2 interacts with genomic loci via binding to DNA as well as histones, and that interaction between MeCP2 and histone proteins plays a key role in gene expression regulation. MeCP2 is a transcriptional repressor and associates with nucleosomes. Here the authors show interaction of MeCP2 and H3K27me3 by biochemical assay and chromatin immunoprecipitation sequencing analysis.

M ethyl CpG binding protein 2 (MeCP2) is highly expressed in neurons, where expression increases postnatally after the final stage of neurogenesis 1,2 . Mutations in the MECP2 gene constitute the primary cause of the neurodevelopmental disorder Rett syndrome (RTT) [3][4][5] . It was hypothesized that MeCP2 functions as a transcriptional repressor that targets methylated DNA at CpG islands to repress transcription 6,7 . Using high throughput assays, several studies demonstrated that, in addition to its affinity to methylated CpG 2 , MeCP2 is also localized to methylated cytosine in the non-CG context (mCH, where H = A, C, or T) and to many nonmethylated loci [8][9][10][11][12] .
We recently found that MeCP2 localization can be predicted by genomic DNA sequence features 13 , particularly regions of high GC content where intrinsic nucleosome occupancy is observed 14,15 . Several studies, including ours, demonstrated that MeCP2 co-localized with nucleosomes or the nucleosome associated protein, histone H1 13,16,17 . In addition, in native coimmunoprecipitation (co-IP) assays, MeCP2 binds to H3K9/ H3K27 methylated nucleosomes in brain tissue 18 . Moreover, in pancreatic adenocarcinoma cell lines, MeCP2 is associated with H3K9 methylation in the IL6 gene region 19 . These studies suggest that MeCP2 affinity to chromatin can be achieved through binding to DNA as well as to histones.
In this study, we demonstrate that MeCP2 can be recruited to genomic loci via binding to H3K27me3 and co-enrichment of MeCP2 and H3K27me3 at transcription start site (TSS) cooperatively regulates gene expression. Our findings indicate that MeCP2, in addition to direct DNA binding, can interact with chromatin via histone protein and that MeCP2 interaction with histone post-translational modifications (PTMs) plays significant roles in transcription regulation.

Results
MeCP2 is associated with nucleosomes in vivo. MeCP2 interacts with several nuclear proteins including DNMT1, CoREST, Suv39H1, and c-SKI [20][21][22] . To further identify and characterize interacting proteins, MeCP2 was immunoprecipitated (IP) from an olfactory epithelium (OE) nuclear extract of wild-type (WT) mice with MeCP2 specific antibody ( Supplementary Fig. 1A). Three distinct bands were identified among co-IPed proteins. One is at~28 kDa (star in Fig. 1a), and two other bands are found between 10 and 15 kDa (arrowheads in Fig. 1a). To identify the 28 kDa band, the band was excised from the gel and analyzed using MALDI-TOF mass spectrometry ( Supplementary Fig. 1C). The sequence of the tryptic peptides, determined by MALDI-TOF, aligns significantly with histone H1 (H1) isoforms (Supplementary Fig. 1D). To confirm the MeCP2 and H1 interaction, we performed MeCP2 IP using Benzonase treated nuclear extracts ( Supplementary Fig. 1B) and validated the presence of H1 (Fig. 1b). We further performed reverse co-IP using a pan H1 antibody. MeCP2 was identified in the H1 co-IPed pool of proteins, determined by Western blotting (Fig. 1b). The other two proteins co-IPed with MeCP2 correspond to histone subunits, histone H3 (H3) and histone H4 (H4), in terms of their molecular weights (arrowheads in Fig. 1a). To test whether MeCP2 is also associated with other histone subunits, the co-IPed proteins from Benzonase treated nuclear extracts were examined for the presence of H3 and H4 by western blotting. Both H3 and H4 were found to be co-precipitated with MeCP2 (Fig. 1c).
With recent findings that MeCP2 and H1 often coexist in the same genomic regions 17 and MeCP2 preferentially locates at GCrich regions 13 , which are populated with nucleosomes 14,15 , we hypothesized that MeCP2 is located in genomic loci through binding to histone proteins. To determine the genome-wide distribution of MeCP2, nucleosomes and H1, we performed H1 chromatin immunoprecipitation sequencing (ChIP-seq) using a pan H1 antibody ( Supplementary Fig. 4A) and compared the results to those of a high-resolution MeCP2 ChIP-seq and MNase-seq data sets 13 (Fig. 1d-f). We compared local enrichment of H1 and nucleosome locations, determined by MNaseseq, to MeCP2-enriched loci on chromosome 19 (chr 19) (Fig. 1d). Within the MeCP2 enriched loci, nucleosome localization and H1 binding demonstrated co-localization. Also, for nucleosome locations on chr 19 defined from MNase-seq, enrichment of MeCP2 and H1 showed high degrees of overlap (Fig. 1e). In a genome-wide correlation analysis between MeCP2 and H1, we observed that the MeCP2 ChIP-seq coverage correlated with that of H1 ChIP-seq genome-wide (r = 0.60) (Fig. 1f). In addition, MNase-seq also moderately correlates with MeCP2 ChIP-seq (r = 0.58) and with H1 ChIP-seq (r = 0.54).
To further confirm that H1 and MeCP2 are localized at the same loci, we performed ChIP-qPCR experiment for selected regions in the 5′UTR of the Bdnf gene, using both H1 and MeCP2 ChIPed DNA. Co-enrichment of H1 and MeCP2 binding was observed for all selected regions tested ( Supplementary Fig. 3A,B). To further confirm the observed co-presence was due to cooccupancy of the same binding site by both MeCP2 and H1, we performed sequential ChIP analysis. MeCP2 ChIPed DNA was subsequently ChIPed with a pan H1 antibody. The resulting DNA was evaluated with qPCR. The re-ChIP analysis confirmed the occupancy of both MeCP2 and H1 in the 5'UTR of the Bdnf gene ( Supplementary Fig. 3A, C). These results altogether indicate that MeCP2 physically associated with the nucleosomal complex.
MeCP2 is highly co-localized with H3K27me3. Despite the significant correlation between MeCP2 and nucleosomes throughout the genome (for example, chr 18: 80,961,548-80,969,056, Fig. 2a center), detailed analysis shows that MeCP2 and nucleosomes do not always co-localize. For example, within chr 2: 109,320,845-109,328,734 ( Fig. 2a left), the nucleosome structure is distinct and MeCP2 binding is low, while within chr 17: 78,596,919-78,604,752 ( Fig. 2a right), MeCP2 binding is robust but nucleosome structure is less stable. To better determine the frequency of MeCP2 and nucleosome colocalization, we utilized the PING software 23,24 . The PING algorithm is designed to detect nucleosome locations with MNase-seq or sonicated-ChIP-seq data. We detected~7672k nucleosome locations and 4257k MeCP2 binding peaks (Fig. 2b). Among those, MeCP2 was absent from 5291k nucleosome locations (68.9% of total nucleosomes), and 2382k nucleosome locations (31.0% of total nucleosomes) were MeCP2-occupied. We also found that 1,876k MeCP2 peaks (44% of total MeCP2 peaks) were observed in nucleosome-free regions. To account for these deviations, the level of DNA methylation was assessed in the following three types of regions: MeCP2-absent mononucleosome loci (group1), MeCP2-enriched mononucleosome loci (group2), and nucleosome-free MeCP2-binding loci (group3). We randomly selected 10,000 loci from each category and compared the methylation status of CpG, CAG, and CAH with whole-genome bisulfite sequencing (WGBS) 13 (Fig. 2c). For the cytosine methylation in CpG, the MeCP2-bound loci were significantly more frequently methylated (median methylation = 50.0% in group1, 76.2% in group2, and 73.9% in group3). In comparison with cytosine methylation in tri-nucleotides (CAG and CAH), the loci from each group were mostly hypo-methylated (median methylation = 0.00% and 0.00% in group1, 0.011% and 0.004% in group2, and 0.009% and 0.006% in group3 for CAG and CAH, respectively). However, the methylation status of the MeCP2 bound loci was still significantly higher than that of MeCP2 non-bound loci. Consistent with previous studies, MeCP2 exhibits affinity to methylated DNA 2,8,9 . To examine the relationship between post-translationally modified histones and MeCP2 enrichment, we performed ChIP-seq for H3K27me3 and H3K9ac using the same genomic DNA used for MeCP2 ChIP-seq 13 (Supplementary Fig. 4B and C). Among chr19 loci, when mononucleosomes are clearly present, MeCP2 levels (group1, n = 101,549; group2, n = 67,051) correlated with the levels of H3K27me3. When nucleosomes were unstable (group3, n = 33,644), MeCP2 enrichment also showed a strong correlation with H3K27me3 while H3K9ac levels are high (Fig. 2d). These results indicate that MeCP2 binding is correlated with H3K27me3.

MeCP2 binds to nucleosomes containing H3K27me3 via MBD.
To test that MeCP2 preferentially binds to H3K27me3, we performed an in vitro pull-down assay to examine whether purified MeCP2 exhibits higher affinity to H3K27me3 containing nucleosomes compared to unmodified nucleosomes. Purified GST-tagged MeCP2 proteins were incubated with either biotintagged unmodified mononucleosomes or H3K27me3 modified mononucleosomes (Fig. 3a). We observed that MeCP2 was more efficiently pulled-down by H3K27me3 modified mononucleosomes, indicating stronger MeCP2 affinity to H3K27me3. This is consistent with our observation that MeCP2 and H3K27me3 can be co-IPed using neuronal tissue ( Supplementary Fig. 5C).
The preference of MBD binding to H3K27me3 rather than unmodified H3 was further investigated by the competition assay. Purified MBD fragments were incubated with nucleosomes containing H3K27me3 (Fig. 3e). H3K27 or H3K27me3 peptides were added and competitive bindings were evaluated. As concentration of H3K27me3 peptide increased, the binding of GST-tagged MBD to nucleosomes containing H3K27me3 decreased. In the meantime, MBD binding to H3K27me3 peptide correspondingly increased (Fig. 3e, g, and Supplementary Fig. 5B).
To further substantiate the specificity in the competition experiment, a peptide with the same sequence of H3K27, but contained no modification, was tested in parallel (Fig. 3e). We observed no obvious competitive binding between H3K27 peptide to MBD-nucleosome complex even at the highest concentration, 10 μM, tested (Fig. 3e, f, and Supplementary Fig. 5B). Thus, comparing to unmodified H3, MBD of MeCP2 shows higher affinity to H3K27me3. Taken together, these results indicate that MeCP2 directly binds to histone H3 via MBD and the binding affinity is preferential to H3K27me3.
Direct association between MeCP2 and H3K27me3 was further tested. If MeCP2 enrichment is directly bound to H3K27me3, it is predicted that an alteration in H3K27me3 levels would change the level of MeCP2 binding on the chromatin. To decrease the H3K27me3 levels, SH-SY5Y cells were treated with GSK343, an inhibitor of H3K27me3-specific histone methyltransferase (HMTase) 25 . After 72 hours of treatment, we observed that the level of H3K27me3 was dramatically decreased, while the level of Ezh2, an H3K27-specific histone methyltransferase, is unchanged ( Supplementary Fig. 6A, B). In addition, the transcription and protein levels of MeCP2 were unchanged after GSK343 treatment (Supplementary Fig. 6A-C). Furthermore, we determined whether GSK343 treatment alters DNA methylation levels using bisulfite pyrosequencing of LINE-1 regions 26   L a n e 1 L a n e 2 L a n e 3 Mono -nucleosome (biotin Tag) H3K27me3 -nucleosome (biotin Tag 72 h had little effect on DNA methylation. Given these findings, we performed immunoprecipitation assays to determine MeCP2 and H3K27me3 interaction. Input from the GSK343-treated cells show less H3K27me3 compared to the DMSO controls as expected (Fig. 4a). More importantly, the IPed histone H3 from GSK343-treated cells contained markedly less MeCP2 than that of DMSO-treated cells. Consistently, reverse co-IP by MeCP2 antibody in GSK343-treated cells showed much lower levels of H3 than that of DMSO-treated cells (Fig. 4a).
In parallel, whether MeCP2 binding to chromatin decreases with reduced H3K27me3 was examined by H3K27me3-and MeCP2 ChIP-seq of DMSO-and GSK343-treated cells (Fig. 4b to d). Consistent with in vivo analysis (Fig. 2g), MeCP2 enrichment in DMSO-treated SH-SY5Y cells shows strong correlation with H3K27me3 (r = 0.74). Differential peak calling analysis comparing DMSO-and GSK343-treated cells shows overall H3K27me3 peak reduction, while a fraction of MeCP2 peaks show variation in localization ( Supplementary Fig. 7A, B). H3K27me3 signal was further normalized with an exogenous reference genome (ChIP-Rx) and determined by reference-adjusted reads per million (RRPM) (Supplementary Fig. 7C). We classified loci, according to the degree of H3K27me3 level changes by GSK343 treatment after RRPM normalization: "unchanged", "moderate" and "severe" (Fig. 4c). The loci in the "moderate" and "severe" groups showed relatively high H3K27me3 enrichment compared the "unchanged" loci. We then compared MeCP2 enrichment after read per million (RPM) normalization by the groups (Fig. 4d). MeCP2 binding in the loci of the "unchanged" group showed a small but significant increase in the GSK343-treated samples compared to DMSO, despite the overall MeCP2 enrichment is low in those regions (median of MeCP2 differences = 0.00, Fig. 4d). Among the loci in the "moderate" group, MeCP2 binding is significantly reduced in GSK343-treated cells compared to that in the control DMSO (median of MeCP2 differences = −0.47, Fig. 4d). Moreover, in the "severe" group, in addition to significant reduction of MeCP2 binding, the degree of MeCP2 reduction (median of MeCP2 differences = −1.5, Fig. 4d) is at a greater degree compared to that of the "moderate" group. We further examined H3K27me3 and MeCP2 enrichment at three loci around the HOXB gene cluster ( Supplementary  Fig. 7F, G). A significant decrease in the MeCP2 binding upon H3K27me3 reduction was observed in these loci as well. Taken together, these results suggest that MeCP2 prefers to bind H3K27me3-modified nucleosome, and that the MeCP2 occupancy genome-wide are influenced by the status of H3K27me3.
MeCP2-H3K27me3 interaction is independent of DNA methylation. To further determine whether MeCP2 binding to H3K27me3 is independent of DNA methylation, we examined MeCP2-chromatin interactions in cells with minimal DNA methylation. DKO1 cells 28 Fig. 8B). MeCP2 enrichment changes were further analyzed in differential methylation regions (DMRs) between HCT116 and DKO1. We reanalyzed the WGBS data of both HCT116 and DKO1 from Blattler et al. 11 , and identified 91,106 DMRs (Supplementary Fig. 8C). In DKO1 cells, there was on average 81.25% reduction in DNA methylation in DMRs when compared to HCT116 cells. Interestingly, MeCP2 enrichment was significantly increased in DMRs of DKO1 (Fig. 5a). These results suggested that DNA methylation is not the only determinant of MeCP2 chromatin interaction. Next, to analyze MeCP2-H3K27me3 interaction in hypomethylated DNA, we analyzed the genome-wide correlations between H3K27me3 and MeCP2 enrichment by ChIP-seq and compared between HCT116 and DKO1. Consistent with neuronal tissue (Fig. 2g) and SH-SY5Y cells (Fig. 4b), MeCP2 enrichment is highly correlated with H3K27me3 in HCT116 cells (r = 0.79). With significant reduction of DNA methylation, in DKO1, we observed a strong correlation between H3K27me3 and MeCP2 binding as well (r = 0.77) (Fig. 5b). More specifically, changes in MeCP2 enrichment at the loci with increased or decreased H3K27me3 were compared (Fig. 5c-f). Consistent with previous studies 11,29 , dynamic redistribution of H3K27me3 was observed throughout the genome of DKO1 compared to that of HCT116. Comparison between HCT116 and DKO1 showed that there was a large number of H3K27me3 enriched loci in DKO1 cells that were not detected in HCT116 (n = 51 K of 166 K, 30.7%); while only a small number of unique H3K27me3 loci were present in HCT116 (n = 5 K of 120 K, 4.4%) (Fig. 5c). This finding indicated that an increased H3K27me3 enrichment appeared in cells with decreased DNA methylation level. Among loci with increased H3K27me3 binding, 5000 loci were randomly selected (Fig. 5d). Analyzing MeCP2 enrichment within these loci, we observed an increase in MeCP2 binding in DKO1 (Fig. 5e). Changes of MeCP2 distribution in DKO1 were further visualized at selected regions ( Fig. 5f). At chr 11: 129,230,000-129,250,000, DNA methylation was significantly depleted in DKO1 cells, while increased H3K27me3 binding was detected in this region. With input normalized ChIP-seq, we observed an increased MeCP2 enrichment within this region. The H3K27me3-dependent MeCP2 binding change was also observed in the H3K27me3 reduced loci in DKO1 (Supplementary Fig. 8D-F). Overall, these results further support that MeCP2 binds to H3K27me3 enriched loci independently of DNA methylation.
MeCP2 binds to transcriptional regulatory loci with H3K27me3. MeCP2-chromatin interaction in mouse OE was abundant among intronic and intergenic regions (Fig. 6a). The regulatory regions, 5'UTR and promoter-TSS, were less abundant with MeCP2 binding when only considering peak numbers.
However, the regulatory regions are under-represented in the mouse genome and intronic and intergenic regions are extensive in length. We statistically evaluated the association between MeCP2 binding frequencies to these regions by taking the structure of genome into account using regioneR 30 , testing overlaps of MeCP2 enriched loci to genomic regions based on permutation sampling. MeCP2 was highly enriched in the 5′UTR, promoter-TSS, and exons by Z score (Z score > 60, Fig. 6b and Supplementary Fig. 9A-C). Conversely, although MeCP2 binding was the most abundant, by absolute count, in intergenic loci genome-wide, its association with each region was not significant based on Z score (Fig. 6b).
The distribution of MeCP2 with epigenetic modifications was further visualized at selected regions to explore the relationship between MeCP2 and epigenetic modifications. At chr 17: 45,680,000 -45,700,000, which includes Tmem151b and Nfkbie, while example correlations were observed between MeCP2 binding and H3K27me3, co-enrichment of MeCP2 and H3K9ac is limited at TSS including 5'UTR (Fig. 6c, top three wiggle tracks). In addition, no distinct co-enrichment between MeCP2 binding and methylated DNA (CpG, CAG, and CAH) was observed (Fig. 6c, bottom three wiggle tracks). At genome-wide level, the co-enrichment of MeCP2 and H3K27me3 or H3K9ac was evaluated in the annotated regions. H3K27me3 peaks were present in 38.13% of MeCP2+/5′UTR regions, 32.48% of MeCP2+/exon regions, and 20.99% of MeCP2+/promoter-TSS regions, whereas comparably less H3K27me3+ enrichment was identified in MeCP2+/intergenic (8.57%) sites. Furthermore, the transcriptional regulatory region including MeCP2+/5′UTR (33.55%) and MeCP2+/promoter-TSS (15.22%) is relatively highly co-enriched with both H3K27me3 and H3K9ac (Fig. 6d). From the canonical point of view that MeCP2 binds to methylated CpG, this strong enrichment of MeCP2 in regions around TSS could be due to a higher level of DNA methylation. We further analyzed MeCP2 binding with the degree of DNA methylation around TSS regions (Fig. 6e). Contrary to the existing notion, the extended region of TSS showed a separation between DNA methylation and MeCP2 binding. The distribution of MeCP2 and histone PTMs, H3K27me3 and H3K9ac, were highly correlated (Fig. 6f). In addition, epigenetic modifications were analyzed in enhancer loci ( Supplementary Fig. 9G), defined by co-enrichment of DNase I hypersensitive sites (DHS), H3K4me1 and H3K27ac 31,32 . Within these enhancer loci, MeCP2, H3K27me3, and H3K9ac were abundant (Fig. 6h); while DNA is hypomethylated (Fig. 6g). These results demonstrate that MeCP2 binding to gene expression regulatory regions is independent of DNA methylation but correlated with both H3K27me3 and H3K9ac.
MeCP2-H3K27me3 cooperatively modulates gene expression. The coexistence of histone PTMs and MeCP2 in transcription regulatory regions implies that they could influence the regulation of gene expression. To examine the relationship between gene expression and MeCP2 binding with histone PTMs in mouse OE, we evaluated RNA-seq data 13 after clustering genes depending on MeCP2 binding and histone PTMs distribution. A super selforganizing map (SuperSOM) clustering algorithm 33 was used to define the characteristics of co-occurrence of MeCP2 and specific histone PTMs. SuperSOM clustering for the region encompassing 1 kb upstream and 5 kb downstream sequences of all genes revealed three discrete clusters: Cluster1, co-enrichment of MeCP2 and H3K27me3 in the TSS and gene body (4812 genes); Cluster2, co-enrichment of MeCP2 and H3K27me3 in the TSS and gene body, and H3K9ac enrichment in TSS (770 genes); and Cluster3, co-enrichment of MeCP2, H3K27me3 and H3K9ac in   the TSS (2101 genes) (Fig. 7a). To determine whether the spatial positioning of MeCP2 with histone PTMs was related to differences in gene expression, we compared the levels of gene expression using three WT biological replicates 13 (Fig. 7b) Supplementary Fig. 9G). h Z-score transformed average enrichment of MeCP2, H3K27me3 and H3K9ac, calculated −3 kb to +3 kb around the midpoint of each enhancer (defined in Supplementary Fig. 9G). The shaded areas are up to ±S.D. from the average profile (e-h).
In order to further confirm these observations, using an amplification-free gene expression analysis (NanoString), we compared the expression differences between WT and KO in genes belonging to each cluster ( Fig. 7f-i, Supplementary Table 4). Consistent with the GSEA analysis, the percentage of upregulated genes in cluster2 (68%, Fig. 7g, i) is higher than those of cluster1 (52%, Fig. 7f, i). A high percentage of up-regulated genes was also measured in cluster3 (89%, Fig. 7h and i). The differential expression of genes belonging to clusters2 and 3 was re-confirmed using RT-qPCR ( Supplementary Fig. 10B, C). These data indicate that MeCP2 suppresses genes modified with high levels of H3K9ac at the TSS.
To perform an unbiased analysis of MeCP2, H3K27me3, and H3K9ac occupancy in regions of differentially expressed genes in   Mecp2 KO mice, we isolated all of upregulated (FDR < 0.05, fold change > 1.3, n = 890) and down-regulated genes (FDR < 0.05, fold change < −1.3, n = 699). MeCP2 binding between 1 kb upstream and 10 kb downstream of each TSS was mapped (Fig. 8a). While MeCP2 binding is abundant among up-regulated genes, particularly at the TSS, the binding is substantially lower within the corresponding region for down-regulated genes. To investigate the relative enrichment of MeCP2 in the intragenic region to that of flanking regions, we compared the average value of the MeCP2 enrichment signal across predefined regions (TSS regions, -1 to 1 kb and gene body, 1 to 10 kb) to that of the proximal regions of the gene body (−6 to −1 kb and transcription -6 kb to -1 kb -1 kb to +1 kb +1 kb to +10 kb TES to +5 kb -6 kb to -1 kb -1 kb to +1 kb +1 kb to +10 kb TES to +5 kb -6 kb to -1 kb -1 kb to +1 kb +1 kb to +10 kb TES to +5 kb log2 (H3K27me3 -Input) H3K27me3 enrichment within the up-regulated genes was also markedly higher than in down-regulated genes (Fig. 8b). When comparing KO vs WT, we also observed in up-regulated genes that H3K27me3 enrichment was significantly higher in the TSS and gene body than in any of the distal regions (median H3K27me3 [log2] for TSS = 0.67, gene body = 0.31, and proximal regions = 0.14). In contrast, H3K27me3 enrichment was restricted to the proximal region of the TSS in downregulated genes (median H3K27me3 [log2] for TSS = 0.04, gene body = −0.21, and proximal regions = −0.16). Overall the H3K27me3 enrichment of both up-and down-regulated genes closely paralleled to the extent and magnitude of MeCP2 enrichment (Fig. 8a, b). Contrary to MeCP2 and H3K27me3, remarkably high enrichment of H3K9ac at the TSS was observed in both up-and down-regulated genes (Fig. 8c). Strong H3K9ac enrichment around the TSS, with little concentration throughout the body of the gene, was observed in both up-and downregulated genes (median H3K9ac [log2] for TSS = 0.93, gene body = 0.26, and proximal regions = 0.04 in up-regulated genes; median H3K9ac [log2] for TSS = -0.01, gene body = -0.35, and proximal regions = -0.29 in down-regulated genes). Therefore, in addition to H3K9ac at the TSS, co-occurrence of MeCP2 and H3K27me3 at the TSS and gene body modulate gene expression (Fig. 8d).

Discussion
MeCP2 has been defined as a methylated DNA-binding protein 2,8,9 . However, there are many exceptions in vivo as to the specificity of MeCP2 binding to methyl-cytosine. Particularly, maintaining MeCP2 bindings in chromatin in Dnmt1, Dnmt3a, Dnmt3b triple knock out ES cells argue that MeCP2 interacts with chromatin via additional mechanisms 35 . In the present study, we show that MeCP2 directly binds to the nucleosome complex and its binding is enhanced by the presence of modified H3, H3K27me3. Furthermore, MeCP2 interactions with H3K27me3 correlate with its role in transcriptional repression.
Under in vitro conditions, it was reported that the C-terminal region of MeCP2 contributes to the formation of complexes with nucleosomes and that the binding was enhanced with methylated DNA 36,37 . An independent study using small angle X-ray scattering technique 38 confirmed that MeCP2 binds near the nucleosomal dyad, close to the linker DNA entry-exit region. Furthermore, genome-wide analyses of MeCP2 binding patterns have shown that MeCP2 enrichment co-occurred at nucleosome positions 8 or histone H1 binding sites 17 . Recently, we also demonstrated that MeCP2 preferentially localizes at GC-rich regions and co-localizes with nucleosomes in a genome-wide study 13 . However, the direct interaction between MeCP2 and nucleosomal protein and the effect of histone modifications on MeCP2 binding to chromatin has not been well studied.
In this study, we provide evidence that MeCP2 physically associates with nucleosomal proteins and co-localizes with mononucleosomes genome-wide (Fig. 1). Specifically, MeCP2 binding is highly correlated with H3K27me3 distribution (Fig. 2). In vitro pull down and immunoprecipitation assay reveals that MeCP2 directly binds to histone H3, and this binding is enhanced by H3K27me3 (Fig. 3). Manipulation of H3K27me3 levels affects genome-wide MeCP2 binding (Fig. 4), suggesting that H3K27me3 is an important factor in determining the recruitment of MeCP2 to specific loci. We also found that MeCP2 binding to chromatin was maintained in hypomethylated cell lines as well as that the alteration of MeCP2 binding correlated with the change in H3K27me3 (Fig. 5). The MBD of MeCP2 has been characterized as a binding region for 5-methylcytosine (mC) 39 by Bird and coworkers, and subsequent studies have shown that MeCP2 also has a high affinity to non-CG methylation (mCH) 8,9 and 5hydroxy methyl cytosine (hmC) 10 . We performed domainspecific characterization on MeCP2's affinity to H3K27me3 and observed higher affinity of MBD to H3K27me3 containing nucleosomes compared to unmodified nucleosomes ( Fig. 3b-g). Considering that the MBD of MeCP2 binds to both methylated (or hydroxylmethylated) cytosine and H3K27me3, the two binding motifs may be competitive to MeCP2 binding, depending on the epigenetic status of the locus. Indeed, it was observed that MeCP2 binding is enriched with H3K27me3 in transcription regulatory regions (TRR) where DNA is hypomethylated (Fig. 6e-h). On the other hand, the enrichment of MeCP2 relative to H3K27me3 levels in the gene body was not as obvious as TRR (Fig. 7a), which possibly means that MeCP2 enrichment is also mediated by other factors such as methylated DNA. In general, considering that DNA is hypermethylated in gene body except for TRR (Fig. 6e), MeCP2 binding in the gene body is likely due to methylated DNA as well as H3K27me3.
Previously, we reported that mCpG% at TSSs was not significantly different between the up-and down-regulated genes, whereas MeCP2 enrichment at TSSs of up-regulated genes is higher than that of the down-regulated genes in Mecp2 KO 13 . In this study, we demonstrate that H3K27me3 at TSSs is significantly higher in up-regulated genes compared to that of the down-regulated genes of Mecp2 KO, and MeCP2 binding for chromatin is also proportional to the level of H3K27me3 in both up and down-regulated transcripts (Fig. 8a, b).
It is well established that H3K27me3 is associated with transcription repression 40,41 . The deposition of H3K27me3 is aggravated when transcription is in an inactive state 42 . It is possible that H3K27me3 enrichment recruits MeCP2 and the H3K27me3 deposition together with MeCP2 is responsible for transcription repression. Therefore, the upregulated genes identified in Mecp2 KO mice may indicate a partial alleviation of transcriptional repression by MeCP2. However, not all genes marked by both MeCP2 and H3K27me3 are upregulated in Mecp2 KO mice. The level of acetylation in H3K9 around the TSS also contributes to gene expression alterations in Mecp2 KO mice (Figs. 6 and 7).
MeCP2 has the ability to bind nucleosomal proteins as shown in Fig. 1b, c. Other histones and their modifications could also contribute to MeCP2 binding to chromatin. For example, MeCP2 competes with histone H1 for chromatin binding 43 and that histone H1.2, a subfamily of histone H1, has binding affinity for H3K27me3 44 . Therefore, it is possible that MeCP2 could compete with histone H1 for binding to H3K27me3. Also, a large proportion of chromatin is modified by more than one epigenetic modification, which suggests that there are complex parameters for controlling the MeCP2 binding affinity to the whole-genome and for gene expression regulation. Therefore, it is necessary to study the interaction with other epigenetic modulations in correlation with MeCP2 to achieve better understanding of MeCP2 function in the regulation of gene expression. Immunoprecipitation assays. To extract nuclei, olfactory epithelium (OE) tissue were isolated and physically dissociated in PBS. The dissociated cells, which are mostly olfactory sensory neurons (OSNs) are spun down 1000×g at 4°C for 10 min, and lysed with lysis buffer (5 mM PIPES, 85 mM KCl, 0.5% IGEPAL CA-630, pH 8.0) with Halt protease and phosphatase inhibitor cocktail (Thermo Scientific, 1861281). Plasma membranes were mechanically disrupted by a homogenizer (Kimble-Kontes. 885300-0002), while the nucleus remains intact after homogenization. Nuclei were pelleted at 2400×g for 10 min at 4°C, resuspend the nuclei pellet in 300 μl of Ab binding and washing buffer (NaCl 150 mM, Tris 50 mM, NP-40 1%, pH 8.0) and sonicated by Bioruptor UCD200 (Diagenode) for 5 min (30 s/ 30 s cycle). 125 U of Benzonase Nuclease (EMD chemical, 70746-3) were added to each sample to digest associated DNA ( Supplementary Fig. 1B) and the protein preparations were saved for Co-IP assay. For Co-IP, 4.8 μg of MeCP2 antibody (Diagenode, pAb-052-050) or 8 μg of pan histone H1 antibody (Santa cruz, sc-34464) or 4.8 μg of rabbit IgG (Millipore, 12-370) as negative control were added to 50 μl of Dynabeads Protein A/G (Invitrogen) and incubated with nuclear extract for 30 min at room temperature. The pull-down complex was boiled in 2x SDS buffer to elute protein for SDS-PAGE gel, and visualized by Coomassie staining.
ChIP-seq in olfactory neuroepithelia. Chromatin immunoprecipitation assays were performed using MAGnify chromatin immunoprecipitation system (Invitrogen, . Specifically, olfactory neuroepithelia were dissected from the nasal cavity and dissociated mechanically via trituration in phosphate buffer saline (PBS). Cross-linking was done by incubating MOE cells with 1% formaldehyde for 5 min. After washing off the formaldehyde, MOE cells were lysed briefly in SDS containing buffer followed by sonication for 15 min with 30 s intervals to shear genomic DNA using Bioruptor UCD200 (Diagenode). The sheared DNA was evaluated by electrophoresis for their size ranging between 200 and 300 bp. Each sheared genomic DNA preparation was split into two equal portions and incubated with either 50 μg of MeCP2 (Diagenode, pAb-052-050) or 15 μg of histone H1 (Santa Cruz, sc-34464) or 10 μg of H3K27me3 (Diagenode, pAb-069-050) or 10 μg of H3K9ac (Diagenode, pAb-177-050). After pulling down magnetically, genomic DNA in the complex was reverse cross-linked by DNase-free Proteinase K and purified. For ChIP-seq experiments, histone H1, H3K27me3, and H3K9ac ChIPed or input DNA were used to prepare the ChIP-seq library as described (NEXTflex ChIP-seq kit, Bio Scientific, NOVA 5143-01 and NEXTflex ChIP-seq Barcodes-6, NOVA 514120) followed by high throughput sequencing with Illumina Hiseq 2000.
For ChIP-qPCR experiment, each sheared genomic DNA preparation was split into two equal portions and incubated with either 2 μg of MeCP2 (Diagenode, pAb-052-050) or 2 μg of histone H1 (Santa Cruz, sc-34464) or Rabbit IgG (Millipore, 12-370) as negative control. To examine MeCP2 binding at Bdnf locus, quantitative real-time PCR was performed on the precipitated DNA fragments using five pairs of oligonucleotide primers designed to produce amplicons covering the MeCP2 binding site in the Bdnf gene and flanking sequences (chr2: 109,514,240-109,517,676, NCBI37/mm9) (for details on primers positions, see Supplementary Fig. 3A and Supplementary Table 5). For Re-ChIP experiments, 25 μl of ReChIP buffer (Dilution Buffer, 10 mM DTT) was added to MeCP2-genomic DNA complex following washes and incubated at 37°C for 30 min. The sample was then diluted 40 times in dilution buffer (Invitrogen, P/N 100006377), and then 2 μg of histone H1 (Santa Cruz, sc-34464) or 2 μg of rabbit IgG (Millipore, 12-370) for the second IP were incubated for 4 h at 4°C. After genomic DNA in the complex was purified, quantitative real-time PCR was performed on the precipitated DNA fragments using two pairs of oligonucleotide primers in flanking regions of Bdnf gene (for details on primers information, see Supplementary Table 5).
NanoString gene expression analysis (mouse OE). Transcriptional levels of WT (GSM3465071 and 3465072) or Mecp2 KO (GSM3465073 and 3465074) OE tissues were measured using pre-made sets of panel, nCounter Mouse Neuropathogy Panel Kit (XT-CSO-MNROP1-12, NanoString Technologies) containing 770 genes. The measurements were performed in biological duplicates. The nSolver Analysis Software 4.0 (NanoString Technologies) were used for data analysis.
Statistics and reproducibility. Regarding to ChIP-seq analyses, extended experimental procedures are included in Supplementary Method section of Supplementary Information. All ChIP-seq assays were performed two times with high reproducibility (Supplementary Fig. 2A-M). All immunoprecipitation assays were performed at least three times (Fig. 1a-c; Fig. 4a; Supplementary Fig. 5C). All pulldown assays were performed at least two times (Fig. 3a, c-e; Supplementary  Fig. 5A, B). All results were successfully repeated. Following experiments were performed once ( Supplementary Figs. 1A, B, 6A, and 8A).
Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
Sequencing data have been deposited into NCBI Gene Expression Omnibus under accession code GSE71126, and GSE122366. The source data underlying Figs. 1b, c, 3a, c-e, 4a and Supplementary Figs. 1A, 6A and 8A are provided as a Source data file. All data is available from the corresponding author upon reasonable request. Source data are provided with this paper.